more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$111.77 USD

-2.70 (-2.36%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $111.72 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids

by Sundeep Ganoria Published on October 14,2022

Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.

Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab

by Kinjel Shah Published on October 13,2022

FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.

pharmaceuticals

Novavax's (NVAX) COVID-19 Booster Recommended in Switzerland

by Zacks Equity Research Published on October 11,2022

The Federal Office of Public Health in Switzerland recommends Novavax's (NVAX) COVID-19 vaccine, Nuvaxovid, as a booster for both heterologous and homologous use in adults aged 18 years and older.

biotechs

Why Novavax's (NVAX) COVID Vaccine Struggles for Market Share?

by Zacks Equity Research Published on October 04,2022

Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

by Zacks Equity Research Published on September 29,2022

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

by Zacks Equity Research Published on September 29,2022

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

by Zacks Equity Research Published on September 27,2022

Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19 booster vaccine in kids. The vaccine is already authorized for use in adolescents and adults.

Why Novavax (NVAX) Stock Was Down 13% on Thursday

by Zacks Equity Research Published on September 23,2022

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research Published on September 21,2022

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

pharmaceuticals

Vaccine Stocks Down After Biden Says Pandemic is Over

by Kinjel Shah Published on September 20,2022

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

vaccines

Pharma Stock Roundup: J&J New Buyback Plan, CHMP Nod to PFE's BA.4, BA.5 Omicron Jab

by Kinjel Shah Published on September 16,2022

J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.

pharmaceuticals

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

by Zacks Equity Research Published on September 15,2022

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.

Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod

by Zacks Equity Research Published on September 13,2022

Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.

vaccines

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

by Zacks Equity Research Published on September 13,2022

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland

by Zacks Equity Research Published on September 05,2022

Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.

Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation

by Zacks Equity Research Published on September 02,2022

The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.